Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Decline in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 159,300 shares, a drop of 25.1% from the October 15th total of 212,600 shares. Based on an average daily trading volume, of 642,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.4% of the company’s stock are sold short.

Hedge Funds Weigh In On Achilles Therapeutics

Several hedge funds have recently modified their holdings of ACHL. BML Capital Management LLC grew its stake in Achilles Therapeutics by 555.8% in the third quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after purchasing an additional 3,474,828 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Achilles Therapeutics by 239.4% in the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock valued at $42,000 after buying an additional 36,441 shares in the last quarter. Ikarian Capital LLC acquired a new position in Achilles Therapeutics during the first quarter worth $1,804,000. StemPoint Capital LP bought a new stake in Achilles Therapeutics during the first quarter worth $1,732,000. Finally, Acadian Asset Management LLC bought a new position in shares of Achilles Therapeutics in the 1st quarter valued at about $350,000. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Stock Performance

NASDAQ ACHL opened at $1.02 on Thursday. Achilles Therapeutics has a 52 week low of $0.63 and a 52 week high of $1.76. The stock’s 50 day moving average price is $0.94 and its two-hundred day moving average price is $0.87.

Achilles Therapeutics (NASDAQ:ACHL) last released its earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.41). Analysts anticipate that Achilles Therapeutics will post -1.7 earnings per share for the current year.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.